ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th Posted on August 16, 2021 by ARCA IT - Press Release, Uncategorized 8.16-Q3-Virtual-Investor-Summit-Annc
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 Posted on August 9, 2021 by ARCA IT - Press Release, Uncategorized 8.9-rNAPc2-COVID-19-Patent-submission-FINAL
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update Posted on August 4, 2021 by ARCA IT - Press Release, Uncategorized 8.4-2Q2021-Financial-Results-and-Business-Update
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology Posted on July 28, 2021 by ARCA IT - Press Release, Uncategorized 7.28-Gencaro-Data-Published-in-Circulation-A-and-E
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 Posted on July 13, 2021 by ARCA IT - Press Release, Uncategorized 7.13-rNAPc2-ASPEN-COVID-Trial-Update
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th Posted on July 9, 2021 by ARCA IT - Press Release, Uncategorized 7.9-Access-to-Giving-Investor-Conference-FINAL
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement Posted on July 7, 2021 by ARCA IT - Press Release, Uncategorized 7.7-rNAPc2-Mainz-Agreement-FINAL
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update Posted on May 11, 2021 by ARCA IT - Press Release, Uncategorized 5.11-1Q2021-Financial-Results-and-Business-Update
Christopher Graybill Joins ARCA as Vice President, Clinical Development Posted on May 5, 2021 by ARCA IT - Press Release, Uncategorized 5.05-Graybill-VP-Clin-Dev
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer Posted on May 3, 2021 by ARCA IT - Press Release, Uncategorized 5.03-CFO-Transition